AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Exact Sciences Corporatio... (EXAS)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

49.71

0.40 (0.81%)

At close: Feb 18, 2025, 3:59 PM

49.94

0.46%

After-hours: Feb 18, 2025, 07:54 PM EST

undefined% (undefined)

Bid	49.94
Market Cap	9.20B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-1.16
PE Ratio (ttm)	-42.85
Forward PE	n/a
Analyst	Buy

Ask	49.95
Volume	2,033,758
Avg. Volume (20D)	2,090,391
Open	50.15
Previous Close	49.31
Day's Range	49.44 - 51.45
52-Week Range	40.62 - 79.62
Beta	undefined

About EXAS

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid th...

[Show more]

Industry Medical - Diagnostics & Research

Sector Healthcare

IPO Date Feb 1, 2001

Employees 6,500

Stock Exchange NASDAQ

Ticker Symbol EXAS

Website https://www.exactsciences.com

Full Company Profile

Analyst Forecast

According to 18 analyst ratings, the average rating for EXAS stock is "Buy." The 12-month stock price forecast is $71, which is an increase of 42.83% from the latest price.

Buy 88.89%

Hold 5.56%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Exact Sciences Corporation is scheduled to release its earnings on Feb 19, 2025, after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 months ago

+9%

Exact Sciences shares are trading higher. The comp... Unlock content with Pro Subscription

3 months ago

-23.48%

Exact Sciences shares are trading lower after the company reported worse-than-expected Q3 financial results and issued FY24 revenue guidance below estimates.

News

1 day ago · businesswire.com

U.S. Patent Trial and Appeal Board Institutes Inter Partes Review Based on Geneoscopy's Petition Challenging Validity of a Second Patent Asserted by Exact Sciences

ST. LOUIS--(BUSINESS WIRE)--Geneoscopy announced that the U.S. Patent Trial and Appeal Board instituted inter partes review of U.S. Patent No. 11,970,746 owned by Exact Sciences.

5 days ago · zacks.com

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

6 days ago · zacks.com

Exact Sciences (EXAS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Exact Sciences (EXAS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago · businesswire.com

Exact Sciences Schedules Fourth Quarter 2024 Earnings Call

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its fourth quarter 2...

3 weeks ago · zacks.com

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

4 weeks ago · businesswire.com

Exact Sciences Demonstrates Leadership in Cancer Innovation with New Data on Screening and Molecular Residual Disease at 2025 ASCO GI Symposium

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, will present 11 abstracts at the American Society of Clinical Oncology...

4 weeks ago · businesswire.com

New Evidence Validates Oncodetect's™ Ability to Detect Molecular Residual Disease and Predict Recurrence in Colorectal Cancer Patients

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, shared clinical validation data for its OncodetectTM MRD test at the 2...

1 month ago · fool.com

2 Healthcare Stocks to Buy Hand Over Fist in January

Stocks tend to perform well in January, but that's not a good reason to invest this month. Strong returns aren't made in a single 30-day period.

1 month ago · benzinga.com

Exact Sciences Sparks Analyst Optimism Amid Competitive Multi-Cancer Test Market

On Sunday, Exact Sciences Corp EXAS reported preliminary fiscal year 2024 sales of $2.76 billion, up 10% year-over-year, compared to consensus of $2.74 billion.

1 month ago · businesswire.com

Exact Sciences Announces Preliminary Fourth Quarter 2024 Results

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company expects to report revenue of $713 mil...

Load More News